Lookup NU author(s): Emeritus Professor Nicol Ferrier
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© The Author(s) 2019.These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.
Author(s): Barnes TRE, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, Gregory CJ, Haddad PM, Howes OD, Jones I, Joyce EM, Lewis S, Lingford-Hughes A, MacCabe JH, Owens DC, Patel MX, Sinclair JMA, Stone JM, Talbot PS, Upthegrove R, Wieck A, Yung AR
Publication type: Review
Publication status: Published
Journal: Journal of Psychopharmacology
Print publication date: 01/01/2020
Online publication date: 12/12/2019
Acceptance date: 02/04/2019
ISSN (print): 0269-8811
ISSN (electronic): 1461-7285
Publisher: SAGE Publications Ltd
PubMed id: 31829775